ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0956

An IL-18-Containing Five-Gene Signature Distinguishes Histologically Identical Dermatomyositis and Lupus Erythematosus Skin Lesions

Alex Tsoi1, Mehrnaz Gharaee-Kermani2, Celine Berthier1, Tori Nault3, Grace Hile2, Shannon Estadt4, Matthew Patrick1, Rachael Wasikowski1, Allison Billi1, Lori Lowe1, Tamra Reed1, Johann Gudjonsson5 and J. Michelle Kahlenberg6, 1University of Michigan, Ann Arbor, 2University of Michigan, Ann Arbor, MI, 3University of Michigan, Canton, MI, 4University of Michigan, Ypsilanti, MI, 5University of Michigan, Ann ArborUniversity of Michigan, 6Division of Rheumatology, University of Michigan, Ann Arbor, MI

Meeting: ACR Convergence 2020

Keywords: dermatomyositis, Inflammation, skin

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 7, 2020

Title: Muscle Biology, Myositis & Myopathies (0955–0959)

Session Type: Abstract Session

Session Time: 10:00AM-10:50AM

Background/Purpose: Skin lesions in dermatomyositis (DM) patients are common, frequently refractory, and have prognostic significance.  Histologically, DM lesions appear similar to cutaneous lupus erythematosus (CLE) lesions and frequently cannot be differentiated.  We thus undertook to examine the transcriptional profile of DM biopsies and compared them to CLE lesions in order to identify unique features.

Methods: For the inquiry cohort, 43 skin biopsies from 36 unique DM patients were identified within the University of Michigan Pathology Database.  Comparative cases of 43 subacute cutaneous lupus erythematosus (SCLE) and 47 discoid lupus erythematosus (DLE) biopsies were similarly acquired. RNA was isolated and expression analysis was completed through the University of Michigan Advanced Genomics core using Affymetrix Human Gene ST 2.1 array plates for transcriptional analysis. Following normalization, 5-fold cross-validation was used to train random forest classifiers for genes that are only up-regulated in the control vs DM comparison microarray but not in the control vs CLE comparison (restricted to genes with p >0.5 and log2 FC< |log21.5|). A secondary validation cohort was analyzed by real-time quantitative PCR and two additional patients underwent single-cell RNA sequencing.  Protein expression was confirmed by immunohistochemistry.

Results: Type I interferon (IFN) signaling, including upregulation of IFN kappa, was a common pathway in both DM and CLE, but CLE also exhibited other inflammatory pathways.  Importantly, DM lesions could be distinguished from CLE by a five-gene biomarker panel that included upregulation of IL18. Using single-cell RNA-sequencing, we further identified keratinocytes and monocyte/macrophages as the source of increased IL-18 in DM skin. 

Conclusion: The novel molecular signature identified in this study has significant clinical implications for differentiating DM from CLE lesions, and we have highlighted the potential role for IL-18 in the pathophysiology of DM skin disease. Further work should examine the potential for anti-IL-18 directed therapies to treat DM skin lesions.


Disclosure: A. Tsoi, None; M. Gharaee-Kermani, None; C. Berthier, None; T. Nault, None; G. Hile, None; S. Estadt, None; M. Patrick, None; R. Wasikowski, None; A. Billi, None; L. Lowe, None; T. Reed, None; J. Gudjonsson, Celgene, 2; J. Kahlenberg, AstraZeneca, 5, Bristol Myers Squibb, 2, 5, Eli Lilly, 5, Avion Pharma, 5, Celgene, 2.

To cite this abstract in AMA style:

Tsoi A, Gharaee-Kermani M, Berthier C, Nault T, Hile G, Estadt S, Patrick M, Wasikowski R, Billi A, Lowe L, Reed T, Gudjonsson J, Kahlenberg J. An IL-18-Containing Five-Gene Signature Distinguishes Histologically Identical Dermatomyositis and Lupus Erythematosus Skin Lesions [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/an-il-18-containing-five-gene-signature-distinguishes-histologically-identical-dermatomyositis-and-lupus-erythematosus-skin-lesions/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/an-il-18-containing-five-gene-signature-distinguishes-histologically-identical-dermatomyositis-and-lupus-erythematosus-skin-lesions/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology